

## Appendix

### **Caspase-8-driven apoptotic and pyroptotic crosstalk drives cell death and IL-1 $\beta$ release in X-linked inhibitor of apoptosis (XIAP) deficiency**


Sebastian A. Hughes *et al.*

Page 2. Appendix Figure S1. The deletion of GSDMD does not delay NLRP3-dependent ASC-oligomerisation upon caspase-8 activation.

Page 3. Appendix Figure S2. Pannexin-1 is required for efficient intrinsic apoptotic activation of NLRP3 but is dispensable for caspase-8-driven NLRP3 activity.


Page 4. Appendix Figure S3. Validation of CRISPR/Cas9 genetic targeting of the cell death machinery in immortalised BMDMs.

Page 5. Appendix Figure S4. Evaluation of inflammasome priming in gene targeted iBMDMs.




**Appendix Figure S1. The deletion of GSDMD does not delay NLRP3-dependent ASC-oligomerisation upon caspase-8 activation.**

BMDMs of the indicated genotypes were seeded at a density of  $2 \times 10^6$  cell per well and primed with 100 ng/ml LPS for three hours before treatment with Cp. A (1  $\mu$ M) or TAK1i (250 nM) for three and six hours. Cells were additionally treated with MCC950 (5  $\mu$ M) for 30 minutes prior to treatment with Cp. A or TAK1i for six hours. PBS insoluble fractions of cell lysates were crosslinked to assess ASC-oligomerisation and these, alongside cell lysates and supernatants, were analysed by western blot. Data represents two independent experiments.




**Appendix Figure S2. Pannexin-1 is required for efficient intrinsic apoptotic activation of NLRP3 but is dispensable for caspase-8-driven NLRP3 activity.**

BMDMs of the indicated genotypes were seeded at a density of  $2 \times 10^6$  cell per well and primed with 100 ng/ml LPS for three hours before treatment with Cp. A (1  $\mu$ M), TAK1i (250 nM) for six hours, ABT-737 (1  $\mu$ M) and CHX (20  $\mu$ g/ml) for four hours, or nigericin (10  $\mu$ M) for 45 minutes. Cell lysates and supernatants were then analysed by western blot. PBS insoluble fractions of cell lysates were crosslinked to assess ASC-oligomerisation and these, alongside cell lysates and supernatants, were analysed by western blot. Ponceau staining depicts protein loading. Data represents one of four independent experiments.



**Appendix Figure S3. Validation of CRISPR/Cas9 genetic targeting of the cell death machinery in immortalised BMDMs.**

iBMDMs of the indicated genotypes were primed with 50 ng/ml LPS for three hours before treatment with Cp. A (1  $\mu$ M) for 24 hours as indicated and total cell lysates were then analysed by western blot. Ponceau staining depicts protein loading. One of two experiments.



**Appendix Figure S4. Evaluation of inflammasome priming in gene targeted iBMDMs.** iBMDMs of the indicated genotypes were untreated or primed with LPS (100 ng/ml) for 0, 2, 4 or 6 hours and total cell lysates analysed by western blot. Ponceau staining depicts protein loading. Data represents one experiment.